Asia

Aim to demonstrate reduction of power consumption by 30% through optimization of energy management
Hitachi, Ltd. announced today that its heavy ion beam therapy system(1) has started treatment at Osaka Heavy Ion Therapy Center as of October 16. This marks the first operation of Hitachi’s first heavy ion therapy system.
The integrated pharma manufacturing group consolidates its portfolio into four businesses- Capsules, Films & Foils, Engineering and Inspection
It has been six years since Johnson & Johnson first launched its JLABS incubators for the life science industry with a vision of providing assistance to startups that could potentially bring about a new paradigm of care for patients.
CBT Pharmaceuticals today announced it has been awarded a Small Business Innovation Research (SBIR) Grant from the U.S. Department of Health and Human Services National Cancer Institute (NCI) of the National Institutes of Health (NIH).
Program part of Itmenan’s ‘Universal Periodic Examination’ & ‘Early Detection of Cancer’ initiatives
MAZ World and ZEAL Cosmetics have confirmed that Ostrich Antibodies are effective in neutralising all four serotypes of Dengue Viruses; providing a new avenue for dengue prevention and/or treatment
Eisai Co., Ltd. has announced that the National Medical Products Administration of China has accepted for review a New Drug Application for Eisai’s antiepileptic drug (AED) perampanel as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older. This NDA is the first to be submitted for perampanel in China.
Eisai Co. and Purdue Pharma announced topline results from their SUNRISE 2 Phase III clinical trial of lemborexant for sleep-wake disorders.
With a new wave of migraine medications now on the market from multiple drugmakers that block the calcitonin gene-related peptide receptor (CGRP-R), Express Scripts has chosen to back two medications and exclude a third from the list of drugs it will carry.
PRESS RELEASES